Bioengineering & Translational Medicine · 2022 · 12 citations · 75 references
MedicineCancer BiologyOncologyDrug DiscoveryMolecular OncologyOncogenesHepatocellular Carcinoma PharmacotherapyMyc Family OncogenesPersonalized Cancer TherapySynthetic LethalitySynthetic Lethality In CancerTargeted Cancer TherapyComputational Target PrioritizationMyc Synthetic LethalityQuadratic OptimizationSynthetic Lethal ScreeningSynthetic Lethality In OncogenesSynthetic Lethality ResistanceTarget PrioritizationTherapeutic Targeting Of Myc
Deregulation of MYC is among the most frequent oncogenic drivers in hepatocellular carcinoma (HCC). Unfortunately, the clinical success of MYC-targeted therapies is limited. Synthetic lethality offers an alternative therapeutic strategy by leveraging on vulnerabilities in tumors with MYC deregulation. While several synthetic lethal targets of MYC have been identified in HCC, the need to prioritize targets with the greatest therapeutic potential has been unmet. Here, we demonstrate that by pairing splice-switch oligonucleotide (SSO) technologies with our phenotypic-analytical hybrid multidrug interrogation platform, quadratic phenotypic optimization platform (QPOP), we can disrupt the functional expression of these targets in specific combinatorial tests to rapidly determine target-target interactions and rank synthetic lethality targets. Our SSO-QPOP analyses revealed that simultaneous attenuation of CHK1 and BRD4 function is an effective combination specific in MYC-deregulated HCC, successfully suppressing HCC progression in vitro. Pharmacological inhibitors of CHK1 and BRD4 further demonstrated its translational value by exhibiting synergistic interactions in patient-derived xenograft organoid models of HCC harboring high levels of MYC deregulation. Collectively, our work demonstrates the capacity of SSO-QPOP as a target prioritization tool in the drug development pipeline, as well as the therapeutic potential of CHK1 and BRD4 in MYC-driven HCC.
75
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally, Miruna Balasundaram, Rebecca Carlsen et al. · Cell · 2017 · 2.6K citations · Full text